Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Treur

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Journal of Medical Economics|May 20, 2017
Cost-effectiveness analysis of rivaroxaban for treatment and secondary prevention of venous thromboembolism in the NetherlandsMarieke Heisen, Maarten J Treur, Harald E Heemstra, et al.
Journal of Theoretical Biology|December 18, 2007
BDI-modelling of complex intracellular dynamicsC M Jonker, J L Snoep, J Treur, et al.
Value in Health Regional Issues|April 29, 2018
Cost-Effectiveness Analysis of Aripiprazole Augmentation Treatment of Patients with Major Depressive Disorder Compared to Olanzapine and Quetiapine Augmentation in Turkey: A Microsimulation ApproachMete Saylan, M J Treur, R Postema, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|April 2, 2009
Efficacy of recombinant activated factor VII vs. activated prothrombin complex concentrate for patients suffering from haemophilia complicated with inhibitors: a Bayesian meta-regressionM J Treur, F McCracken, B Heeg, et al.
Journal of Medical Economics|February 16, 2012
Estimating the quality-of-life impact and cost-effectiveness of alpha-blocker and anti-muscarinic combination treatment in men with lower urinary tract symptoms related to benign prostatic hyperplasia and overactive bladderBram G Verheggen, Richard Lee, Michelle M Lieuw On, et al.
Journal of Medical Economics|June 29, 2012
Fingolimod reduces direct medical costs compared to natalizumab in patients with relapsing-remitting multiple sclerosis in The NetherlandsM Heisen, M J Treur, W S van der Hel, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Journal of Medical Economics|May 20, 2017
Cost-effectiveness analysis of rivaroxaban for treatment and secondary prevention of venous thromboembolism in the NetherlandsMarieke Heisen, Maarten J Treur, Harald E Heemstra, et al.
Journal of Theoretical Biology|December 18, 2007
BDI-modelling of complex intracellular dynamicsC M Jonker, J L Snoep, J Treur, et al.
Value in Health Regional Issues|April 29, 2018
Cost-Effectiveness Analysis of Aripiprazole Augmentation Treatment of Patients with Major Depressive Disorder Compared to Olanzapine and Quetiapine Augmentation in Turkey: A Microsimulation ApproachMete Saylan, M J Treur, R Postema, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|April 2, 2009
Efficacy of recombinant activated factor VII vs. activated prothrombin complex concentrate for patients suffering from haemophilia complicated with inhibitors: a Bayesian meta-regressionM J Treur, F McCracken, B Heeg, et al.
Journal of Medical Economics|February 16, 2012
Estimating the quality-of-life impact and cost-effectiveness of alpha-blocker and anti-muscarinic combination treatment in men with lower urinary tract symptoms related to benign prostatic hyperplasia and overactive bladderBram G Verheggen, Richard Lee, Michelle M Lieuw On, et al.
Journal of Medical Economics|June 29, 2012
Fingolimod reduces direct medical costs compared to natalizumab in patients with relapsing-remitting multiple sclerosis in The NetherlandsM Heisen, M J Treur, W S van der Hel, et al.
Pageof 1